Clinical Trial Update: Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lenalidomide with or without ixazomib and dexamethasone in patients with residual multiple myeloma after donor stem cell transplant h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• NINLARO (ixazomib)
• Revlimid (lenalidomide)

Snippet

Sponsor: University of Chicago | Conditions: Plasma Cell Myeloma, Residual Disease | Phase 2 | Status: COMPLETED | Results posted: 2026-01-22